RECENT TRIALS

Vectra InVolved Informed Decision Outcome Study (VIVID): A prospective randomized controlled trial evaluating the effect of guided care with Vectra on compared to treatment as usual in patients with rheumatoid arthritis

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

CHRONICLE - A Longitudinal Prospective Obersvational Study of the Characteristics, Treatment Patterns and Health Outcome of Individuals with Severe Asthma in the United States

An Open-Label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe Pruritus

RHAPSODY - Phase 3, double-blinded, placebo-controlled, randomized withdrawal study with open-label extension, to assess the efficacy and safety of rilonacept treatment in subjects with recurrent pericarditis

A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study Of The Effects Of Sparsentan, A Dual Endothelin Receptor And Angiotensin Receptor Blocker, On Renal Outcomes In Patients With Primary Focal Segmental Glomerulosclerosis (Fsgs)

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy

Benefits Of Microcor In Ambulatory Decompensated Heart Failure

PHREEDOM - A 26-Week, Phase 3, Open Label Study with a 12-Week, PlaceboControlled, Randomized Withdrawal Period Followed by an Open Label Long Term Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis and Peritoneal Dialysis

HEARIT-Registry - Heart Sounds Registry in Patients Using the Wearable Cardioverter Defibrillator

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety And Efficacy of Intravenous Cr845 In Hemodialysis Patients with Moderate-To-Severe Pruritus, With A 52-Week Open-Label Extension

GALACTIC-HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction

CLCZ696BUS05

CHAMP-HF - Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction

INNO2VATE - CONVERSION - Phase 3, Randomized, Open-Label, ActiveControlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis Dependent Chronic Kidney Disease (DD-CKD)

PRO2TECT – CORRECTION - Phase 3, Randomized, Open-Label, ActiveControlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

PRO2TECT - CONVERSION - Phase 3, Randomized, Open-Label, ActiveControlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

ChaRactErization of patients following aCute venous thrOmboembolism (VTE) and assessment of safety and effectiveness of dabigatran etexilate (DE) in the tReatment and secondary prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice - RE-COVERY DVT/PE

A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia and non- dialysis-dependent chronic kidney disease

EVALUATE-HF - A multicenter, randomized, double-blind, double-dummy, parallel group, active-controlled, forced-titration, 12-week comparison of combined angiotensin-neprilysin inhibition with sacubitril and valsartan versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction (HFrEF)

SONAR - A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo- Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy

Need more details? Contact us

We are here to assist. Contact us by phone or email!